Cargando…
Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy
BACKGROUND: This study aimed to determine the incidence of new onset hepatic steatosis after neoadjuvant chemotherapy for pancreatic cancer and its impact on outcomes after pancreatoduodenectomy. METHODS: Retrospective review identified patients who received neoadjuvant chemotherapy for pancreatic a...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363010/ https://www.ncbi.nlm.nih.gov/pubmed/32671796 http://dx.doi.org/10.1007/s11605-020-04723-2 |
_version_ | 1783559594864279552 |
---|---|
author | Flick, K. F. Al-Temimi, M. H. Maatman, T. K. Sublette, C. M. Swensson, J. K. Nakeeb, A. Ceppa, E. P. Nguyen, T. K. Schmidt, C. M. Zyromski, N. J. Tann, M. A. House, M. G. |
author_facet | Flick, K. F. Al-Temimi, M. H. Maatman, T. K. Sublette, C. M. Swensson, J. K. Nakeeb, A. Ceppa, E. P. Nguyen, T. K. Schmidt, C. M. Zyromski, N. J. Tann, M. A. House, M. G. |
author_sort | Flick, K. F. |
collection | PubMed |
description | BACKGROUND: This study aimed to determine the incidence of new onset hepatic steatosis after neoadjuvant chemotherapy for pancreatic cancer and its impact on outcomes after pancreatoduodenectomy. METHODS: Retrospective review identified patients who received neoadjuvant chemotherapy for pancreatic adenocarcinoma and underwent pancreatoduodenectomy from 2013 to 2018. Preoperative computed tomography scans were evaluated for the development of hepatic steatosis after neoadjuvant chemotherapy. Hypoattenuation included liver attenuation greater than or equal to 10 Hounsfield units less than tissue density of spleen on noncontrast computed tomography and greater than or equal to 20 Hounsfield units less on contrast-enhanced computed tomography. RESULTS: One hundred forty-nine patients received neoadjuvant chemotherapy for a median of 5 cycles (interquartile range (IQR), 4–6). FOLFIRINOX was the regimen in 78% of patients. Hepatic steatosis developed in 36 (24%) patients. The median time from neoadjuvant chemotherapy completion to pancreatoduodenectomy was 40 days (IQR, 29–51). Preoperative biliary stenting was performed in 126 (86%) patients. Neoadjuvant radiotherapy was delivered to 23 (15%) patients. Female gender, obesity, and prolonged exposure to chemotherapy were identified as risk factors for chemotherapy-associated hepatic steatosis. Compared with control patients without neoadjuvant chemotherapy-associated hepatic steatosis, patients developing steatosis had similar rates of postoperative pancreatic fistula (8% (control) vs. 4%, p = 0.3), delayed gastric emptying (8% vs. 14%, p = 0.4), and major morbidity (11% vs. 15%, p = 0.6). Ninety-day mortality was similar between groups (8% vs. 2%, p = 0.08). CONCLUSION: Hepatic steatosis developed in 24% of patients who received neoadjuvant chemotherapy but was not associated with increased morbidity or mortality after pancreatoduodenectomy. |
format | Online Article Text |
id | pubmed-7363010 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-73630102020-07-16 Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy Flick, K. F. Al-Temimi, M. H. Maatman, T. K. Sublette, C. M. Swensson, J. K. Nakeeb, A. Ceppa, E. P. Nguyen, T. K. Schmidt, C. M. Zyromski, N. J. Tann, M. A. House, M. G. J Gastrointest Surg SSAT Plenary Presentation BACKGROUND: This study aimed to determine the incidence of new onset hepatic steatosis after neoadjuvant chemotherapy for pancreatic cancer and its impact on outcomes after pancreatoduodenectomy. METHODS: Retrospective review identified patients who received neoadjuvant chemotherapy for pancreatic adenocarcinoma and underwent pancreatoduodenectomy from 2013 to 2018. Preoperative computed tomography scans were evaluated for the development of hepatic steatosis after neoadjuvant chemotherapy. Hypoattenuation included liver attenuation greater than or equal to 10 Hounsfield units less than tissue density of spleen on noncontrast computed tomography and greater than or equal to 20 Hounsfield units less on contrast-enhanced computed tomography. RESULTS: One hundred forty-nine patients received neoadjuvant chemotherapy for a median of 5 cycles (interquartile range (IQR), 4–6). FOLFIRINOX was the regimen in 78% of patients. Hepatic steatosis developed in 36 (24%) patients. The median time from neoadjuvant chemotherapy completion to pancreatoduodenectomy was 40 days (IQR, 29–51). Preoperative biliary stenting was performed in 126 (86%) patients. Neoadjuvant radiotherapy was delivered to 23 (15%) patients. Female gender, obesity, and prolonged exposure to chemotherapy were identified as risk factors for chemotherapy-associated hepatic steatosis. Compared with control patients without neoadjuvant chemotherapy-associated hepatic steatosis, patients developing steatosis had similar rates of postoperative pancreatic fistula (8% (control) vs. 4%, p = 0.3), delayed gastric emptying (8% vs. 14%, p = 0.4), and major morbidity (11% vs. 15%, p = 0.6). Ninety-day mortality was similar between groups (8% vs. 2%, p = 0.08). CONCLUSION: Hepatic steatosis developed in 24% of patients who received neoadjuvant chemotherapy but was not associated with increased morbidity or mortality after pancreatoduodenectomy. Springer US 2020-07-15 2020 /pmc/articles/PMC7363010/ /pubmed/32671796 http://dx.doi.org/10.1007/s11605-020-04723-2 Text en © The Society for Surgery of the Alimentary Tract 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | SSAT Plenary Presentation Flick, K. F. Al-Temimi, M. H. Maatman, T. K. Sublette, C. M. Swensson, J. K. Nakeeb, A. Ceppa, E. P. Nguyen, T. K. Schmidt, C. M. Zyromski, N. J. Tann, M. A. House, M. G. Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy |
title | Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy |
title_full | Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy |
title_fullStr | Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy |
title_full_unstemmed | Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy |
title_short | Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy |
title_sort | hepatic steatosis after neoadjuvant chemotherapy for pancreatic cancer: incidence and implications for outcomes after pancreatoduodenectomy |
topic | SSAT Plenary Presentation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363010/ https://www.ncbi.nlm.nih.gov/pubmed/32671796 http://dx.doi.org/10.1007/s11605-020-04723-2 |
work_keys_str_mv | AT flickkf hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy AT altemimimh hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy AT maatmantk hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy AT sublettecm hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy AT swenssonjk hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy AT nakeeba hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy AT ceppaep hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy AT nguyentk hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy AT schmidtcm hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy AT zyromskinj hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy AT tannma hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy AT housemg hepaticsteatosisafterneoadjuvantchemotherapyforpancreaticcancerincidenceandimplicationsforoutcomesafterpancreatoduodenectomy |